| Autor: |
P. Martín Padilla-Machaca, Cristopher Dávila, Bertha Cárdenas, Carmen Cerrón, Alberto Mantilla, José Rivera, Alfonso Solar, Augudberto Montufar, Saul Espinoza, Carlos Rondón |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 24, Iss , Pp 100448- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2021.100448 |
| Popis: |
Introduction: Tacrolimus is the basis of immunosuppressive treatment in liver transplantation, with dosages of blood levels to ensure adequate graft function. In Peru, since 2005 generic tacrolimus has been used exclusively in all transplant centers due to lower costs. There are no presentations (0.5 mg), necessary for its use in a group of transplanted patients who require low doses of the drug. Objectives: To show the results of the use of low doses ( 3 months use of generic tacrolimus (NORGRAF: The Madras Pharmaceuticals, India) using 0.5 mg capsules, prepared by the Pharmacy Service at the Guillermo Almenara Hospital. Exclusion criteria: Pediatrics, retransplant, combined transplant. Statistical analysis and processing was using SPSS 23. Results: Eleven of 246 patients (4.52%) were identified. All patients had blood levels within the therapeutic range in relation to transplantation time and graft function. Average daily dose: 1.3 mg (0.5-1.5 mg /d). Average blood levels: 5.82 ng/L (3.57-10.3 ng / ml). Average transplant time: 73 months (3-120 months). There were no rejection episodes or adverse effects of nephrotoxicity, neurotoxicity, or infections. Conclusion: The use of low doses of generic tacrolimus ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
